Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-15 4:45 pm Purchase | 13D | Mersana Therapeutics Inc. MRSN | Bain Capital Life Sciences Fund II L.P. | 4,968,006 4.000% | 926,273 (+22.92%) | View |
| 2024-11-14 5:45 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | Nextech Crossover I GP S.a r.l. | 12,067,246 9.800% | 5,818,403 (+93.11%) | View |
| 2024-11-14 06:01 am Sale | 13G | Mersana Therapeutics Inc. MRSN | BALYASNY ASSET MANAGEMENT L.P. | 535,819 0.440% | -9,162,328 (-94.48%) | View |
| 2024-10-15 06:55 am Sale | 13G | Mersana Therapeutics Inc. MRSN | SILVERARC CAPITAL MANAGEMENT LLC | 1,754,086 1.430% | -4,666,050 (-72.68%) | View |
| 2024-05-17 08:26 am Purchase | 13G | Mersana Therapeutics Inc. MRSN | Nextech Crossover I GP S.a r.l. | 6,248,843 5.100% | 6,248,843 (New Position) | View |
| 2024-02-14 8:56 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | Venrock Healthcare Capital Partners III L.P. | 11,328,000 9.400% | 1,650,000 (+17.05%) | View |
| 2024-02-14 8:43 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | SILVERARC CAPITAL MANAGEMENT LLC | 6,420,136 5.300% | 6,420,136 (New Position) | View |
| 2024-02-14 6:55 pm Sale | 13G | Mersana Therapeutics Inc. MRSN | ORBIMED ADVISORS LLC | 0 0.000% | -7,082,837 (Position Closed) | View |
| 2024-02-14 09:20 am Sale | 13G | Mersana Therapeutics Inc. MRSN | Avoro Capital Advisors LLC | 0 0.000% | -7,550,000 (Position Closed) | View |
| 2024-02-14 07:22 am Purchase | 13G | Mersana Therapeutics Inc. MRSN | BALYASNY ASSET MANAGEMENT L.P. | 9,698,147 8.040% | 9,698,147 (New Position) | View |
| 2024-02-13 5:09 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | VANGUARD GROUP INC | 6,237,588 5.170% | 1,788,548 (+40.20%) | View |
| 2024-01-29 3:26 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | BlackRock Inc. BLK | 7,844,282 6.500% | 352,353 (+4.70%) | View |
| 2024-01-22 1:36 pm Sale | 13G | Mersana Therapeutics Inc. MRSN | STATE STREET CORP STT | 2,329,434 1.930% | -3,526,627 (-60.22%) | View |
| 2023-08-07 4:15 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | Venrock Healthcare Capital Partners III L.P. | 9,678,000 8.500% | 9,678,000 (New Position) | View |
| 2023-07-27 5:11 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | EcoR1 Capital LLC | 19,364,688 16.900% | 19,364,688 (New Position) | View |
| 2023-02-14 4:43 pm Purchase | 13G | Mersana Therapeutics Inc. MRSN | ORBIMED ADVISORS LLC | 7,082,837 7.100% | 7,082,837 (New Position) | View |
| 2023-02-14 4:18 pm Sale | 13G | Mersana Therapeutics Inc. MRSN | BB BIOTECH AG | 4,066,200 4.100% | -68,800 (-1.66%) | View |
| 2023-02-14 09:38 am Purchase | 13G | Mersana Therapeutics Inc. MRSN | Avoro Capital Advisors LLC | 7,550,000 7.600% | 750,000 (+11.03%) | View |
| 2023-02-13 6:04 pm Sale | 13G | Mersana Therapeutics Inc. MRSN | Rho Ventures V L.P. | 604,213 0.600% | -726,974 (-54.61%) | View |
| 2023-02-09 11:27 am Purchase | 13G | Mersana Therapeutics Inc. MRSN | VANGUARD GROUP INC | 4,449,040 4.460% | 841,609 (+23.33%) | View |